One of the fastest-growing segments of pharmaceuticals, as highlighted at the 2024 J.P. Morgan Healthcare Conference, is the antibody-drug conjugate (ADC) segment. ADCs consist of four main elements: ...

Discover the top 3 manufacturing mistakes CDMOs make and how to prevent them when scaling for next-generation oncology.

Antibody-drug conjugates (ADCs) have revolutionized the oncology field, offering targeted cancer treatments that improve efficacy without adversely affecting healthy cells. 1 ADCs’ potential extends ...

DUBLIN--(BUSINESS WIRE)--The "Cancer Antibody Drug Conjugates Market Size, Drugs Approval, Price, Sales & Clinical Trials Insight 2030" report has been added to ResearchAndMarkets.com's offering.

Unchained Labs, the life sciences company that's all about getting biologics and gene therapy researchers the right tool for the job, just launched a brand-new application on Stunner today that ...

Glycosite-specific conjugation has emerged as a gold standard for developing next-generation Antibody-Drug Conjugates (ADCs) and other XDCs. However, most existing approaches are hindered by ...

Biohaven enters a significant research collaboration with Merus, enhancing its capabilities in developing novel bispecific antibody drug conjugates, which could lead to innovative cancer therapies.

DEM BioPharma, Inc. (DEM Bio), a biopharmaceutical company dedicated to discovering novel targets for solid tumors and developing innovative, first-in-class, cancer medicines, today announced that ...